Odonate Therapeutics, Inc. (ODTC)
| Market Cap | 67.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -102.07M |
| Shares Out | 38.49M |
| EPS (ttm) | -2.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,408 |
| Open | 1.80 |
| Previous Close | 1.80 |
| Day's Range | 1.80 - 1.80 |
| 52-Week Range | 0.81 - 2.00 |
| Beta | 0.10 |
| Analysts | Sell |
| Price Target | 4.08 (+126.67%) |
| Earnings Date | n/a |
About ODTC
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ODTC stock is "Sell." The 12-month stock price forecast is $4.08, which is an increase of 126.67% from the latest price.
News
Grabar Law Office Investigates Potential Claims Against Officers and Directors of Odonate Therapeutics, Inc. After an Agreement to Settle Class Action for $12.5 Million
Philadelphia, Pennsylvania--(Newsfile Corp. - May 26, 2022) - Odonate Therapeutics Inc. (NASDAQ: ODT) (OTC: ODTC) has agreed to pay $12.5 million to resolve a proposed securities class action in alleg...
Grabar Law Office Investigates Potential Claims Against Officers and Directors of Odonate Therapeutics, Inc. After an Agreement Is Reached to Settle Class Action
Philadelphia, Pennsylvania--(Newsfile Corp. - May 10, 2022) - Odonate Therapeutics Inc. (NASDAQ: ODT) (OTC Pink: ODTC) has agreed to pay $12.5 million to resolve a proposed securities class action in ...
Odonate Announces Expected Delisting of Its Stock
NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate tha...
Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan
NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders...
Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021
NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95....
SHAREHOLDER ALERT: Odonate Therapeutics, Inc. (ODT) Officers and Directors Under Investigation for Possible False Statements to Investors
SAN FRANCISCO, Aug. 13, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Odonate Therapeutics, Inc. (NASDAQ: ODT) relating ...
The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)---- $ODT #investors--The Law Offices of Frank R. Cruz Announces Investigation of Odonate Therapeutics, Inc. (ODT) on Behalf of Investors
Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021
NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinua...
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the bi...
Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021
NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of devel...
Odonate Therapeutics (ODT) Enters Oversold Territory
Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock
Odonate Therapeutics (ODT) is Oversold: Can It Recover?
Odonate Therapeutics (ODT) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Do Options Traders Know Something About Odonate Therapeutics (ODT) Stock We Don't?
Investors need to pay close attention to Odonate Therapeutics (ODT) stock based on the movements in the options market lately.
Why GRPN Stock And ODT Stock Are Trading Lower Today
Groupon Inc (NASDAQ: GRPN) shares are trading lower Monday after the company announced a proposed private offering of $200 million of convertible senior notes. Groupon acts as the middleman between co...
Odonate Therapeutics stock plummets toward record low after plan to 'wind down' operations
Shares of Odonate Therapeutics Inc. plummeted 79.0% in active afternoon trading Monday, after the pharmaceutical company said it will wind down operations following disappointing data from its cancer ...
Why Odonate, Marker Therapeutics and Dyadic Are Moving Monday
Odonate Therapeutics, Inc. (NASDAQ: ODT), Dyadic International, Inc. (NASDAQ: DYAI) and Marker Therapeutics, Inc. (NASDAQ: MRKR) are among the early biotech movers in Monday's session. Odonate to Shut...
Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel
NEW YORK--(BUSINESS WIRE)--Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ: ODT) has concluded that the cl...
Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020
NEW YORK--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients w...
Notable Insider Buys Of The Past Week: Danimer Scientific, Cheniere Energy Partners And More
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can...
3 Beaten-Down Stocks Insiders Scooped Up as 2020 Ended
Fidelity National, Odonate Therapeutics, and Steel Partners all sank by double-digit percentages in 2020. Company executives and directors bought up the stocks.
Notable Insider Buys In The Week Of Christmas: Foot Locker, GameStop, NetApp And More
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can...
Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of patients ...
Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast Cancer
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients ...
Odonate Therapeutics to Host Virtual Investor and Analyst Event on December 11, 2020
SAN DIEGO--(BUSINESS WIRE)--Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients ...
ODT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of November 16, 2020 in the Class Action Filed on Behalf of Odonate Therapeutics, Inc. Limited Shareholders
New York, New York--(Newsfile Corp. - November 16, 2020) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Odonate Therapeutics, Inc. (NASDAQ: O...